Correction: evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines
- PMID: 25876069
- PMCID: PMC4395435
- DOI: 10.1371/journal.pone.0124893
Correction: evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0078053.].
Erratum for
-
Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines.PLoS One. 2013 Oct 22;8(10):e78053. doi: 10.1371/journal.pone.0078053. eCollection 2013. PLoS One. 2013. PMID: 24167597 Free PMC article. Clinical Trial.
References
-
- Jennings BA, Loke YK, Skinner J, Keane M, Chu GS, Turner R, et al. (2013) Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines. PLoS ONE 8(10): e78053 doi: 10.1371/journal.pone.0078053 - DOI - PMC - PubMed